The family of ADAM (a disintegrin and metalloproteinase) proteins has been implicated in tumor initiation and progression. ADAM17/tumor necrosis factor-a (TNFa)-converting enzyme (TACE) has been initially recognized to release TNFa as well as its receptors (TNFRs) from the membrane. ADAM17, TNFa and TNFR have been found upregulated in cancer patients, although the underlying mechanisms remain largely unknown. As hypoxia is a hallmark of cancer that can lead to severe stress conditions accumulating in endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), we investigated the role of these stress conditions in the regulation of ADAM17 and release of TNFR1.We found that severe hypoxia induced ADAM17 expression and activity. Although hypoxia-inducible factor 1a (HIF1a) was important to maintain basal ADAM17 mRNA levels during moderate hypoxia, it was not sufficient to induce ADAM17 levels under severe hypoxia. Instead, we found that ADAM17 induction by severe hypoxia can be mimicked by ER stressors such as Thapsigargin and occurs as a consequence of the activation of the PERK/eIF2a/ATF4 and activating transcription factor 6 (ATF6) arms of UPR in several tumor cell lines. ADAM17 expression was also increased in xenografts displaying ER stress because of treatment with the vascular endothelial growth factor (VEGF) inhibitory antibody Bevacizumab. Additionally, severe hypoxia and ER stress activated ADAM17 and ectodomain shedding of TNFR1 involving mitogen-activated protein (MAP) kinases and reactive oxygen species (ROS). Collectively, these results show that ADAM17 is a novel UPRregulated gene in response to severe hypoxia and ER stress, which is actively involved in the release of TNFR1 under these conditions. These data provide a novel link between severe hypoxic stress conditions and inflammation in the tumor environment.
Introduction
An inflammatory microenvironment including inflammatory cells, chemokines and cytokines and often enhanced levels of reactive oxygen species (ROS) is present in many tumors (Mantovani et al., 2008) and has been linked to tumor progression and metastasis (Grivennikov et al., 2010) . One of the key inflammatory mediators in the pathogenesis of cancer is tumor necrosis factor-a (TNFa) (Aggarwal et al., 1985) . TNFa was initially considered as a potent anticancer agent and was used in sarcoma (Eggermont et al., 2003) and melanoma therapy (Fraker et al., 1996) . Systemic toxicity caused by large amounts of TNFa limited the therapeutic usefulness of TNFa (Feinberg et al., 1988) . Membrane-bound TNFa is also highly expressed in tumors, and subsequent studies showed that it contributes to tumorigenesis by mediating proliferation, angiogenesis, invasion and metastasis (Aggarwal, 2003) . Therefore, targeting the inflammatory environment and TNFa in tumors was suggested for anticancer treatment (Karin and Greten, 2005; Balkwill, 2009) .
The biological responses to TNFa are mediated through TNF receptor 1 (TNFR1), which is expressed on most cells types, and TNF receptor 2 (TNFR2), which is primarily expressed on hematopoietic cells (Loetscher et al., 1990; Schall et al., 1990) . Transmembrane TNFa and its two receptors also exist as soluble forms as a result of shedding of extracellular domains (Engelmann et al., 1990; Heller et al., 1990; Nophar et al., 1990) . In addition to circulating TNFa, the levels of soluble TNFR (sTNFR) have been suggested to reflect the activation state of the TNFa/TNFR system (Diez-Ruiz et al., 1995) . Elevated sTNFR levels have been observed in cancer patients as compared with normal controls and correlated with staging of disease and shorter progression-free survival (Aderka et al., 1991; Langkopf and Atzpodien, 1994; Reibnegger et al., 1994; Viac et al., 1996) .
Although several functions of sTNFR have been discussed including desensitization of cells from the effects of circulating TNFa or augmenting soluble TNFa function by stabilizing it in its homotrimeric form (Van Zee et al., 1992; Waetzig et al., 2005) , the origin and mechanisms involved in the increase of sTNFR in cancer patients, as well as the functional implications, remain to be fully elucidated.
Membrane-bound TNFa and TNFR are processed to their soluble forms by TNFa-converting enzyme (TACE), which is identical to ADAM17 (a disintegrin and metalloprotease 17) (Black et al., 1997) . ADAM family members are composed of common domains including propeptide, metalloproteinase, disintegrin, cysteine-rich, epidermal-growth factor-like, transmembrane and cytoplasmic domains (Mochizuki and Okada, 2007) . ADAM17 is synthesized as inactive zymogen where the active site is blocked by an intramolecular complex between an unpaired cysteine residue of the prodomain and a zinc atom in the catalytic domain (Milla et al., 1999) . Activation of ADAM17 sheddase function is known to be regulated at different levels (Seals and Courtneidge, 2003) . Dissociation of the prodomain can be stimulated by redox changes in sulfhydryl groups in the disintegrin/cysteine-rich region, referred to as the 'cysteine-switch' mechanism of activation. Subsequent removal of the prodomain is mediated by furin and related proprotein convertases (Pei and Weiss, 1995; Srour et al., 2003) . In addition, the cytoplasmic tail of ADAM17 provides binding sites for SH3 (Src homology-3) domain-containing proteins, and serine, threonine and tyrosine residues that are potential sites for phosphorylation by diverse kinases. ADAM17 phosphorylation can regulate protease function in response to intracellular signaling events (that is, inside-out signaling), but may also be involved in outside-in signaling following engagement of its ectodomain with substrates or adhesion partners (DiazRodriguez et al., 2002; Xu and Derynck, 2010) . Endogenously, catalytically active ADAM17 can be inhibited by forming a noncovalent complex with the tissue inhibitor of metalloproteinases-3 (Amour et al., 1998) .
ADAM17 is overexpressed in several human cancers including breast (McGowan et al., 2007) , gastric (Yoshimura et al., 2002; Blanchot-Jossic et al., 2005; Nakagawa et al., 2009) , ovary (Tanaka et al., 2005) and prostate cancer (McCulloch et al., 2000) . Increased expression of ADAM17 and the proportion of active to precursor ADAM17 correlated with variables of progressive disease and predicted for poor survival (McGowan et al., 2007) . Gain-and loss-of-function studies in MDA231 and MCF7 cells indicated that ADAM17 promoted viability, proliferation, endothelial tube formation and invasiveness of cancer cells in vitro (McGowan et al., 2007; Zheng et al., 2009 ) and a malignant phenotype of breast epithelial cells in threedimensional culture models (Kenny and Bissell, 2007) . Paradoxically, there is little known about the signaling pathways involved in upregulation of ADAM17 expression in tumors.
The majority of tumors contain regions of poor oxygenation and hypoxia. Tumor hypoxia correlates with poor prognosis and confers chemo-and radioresistance (Brown and Wilson, 2004) . Additional evidence suggests that tumor inflammation as a cause or consequence of tumor hypoxia may be an aggravating determinant for tumor progression, invasion and resistance to therapy (Finger and Giaccia, 2010) .
The adaptive transcriptional response to hypoxia is controlled primarily by hypoxia-inducible transcription factors (HIF1, HIF2, HIF3), which induce a large number of genes involved in glycolysis, angiogenesis, pH regulation and cell motility (Harris, 2002; Semenza, 2003; Coleman and Ratcliffe, 2007) . However, exposure to severe hypoxia below 0.1% O 2 leads to activation of the endoplasmic reticulum (ER) stress sensors protein kinase RNA activated (PKR)-like ER kinase (PERK), inositol-requiring protein 1 (IRE1) and activating transcription factor 6 (ATF6) (Koumenis et al., 2002b) . As a result, the unfolded protein response (UPR) is induced (Koumenis and Wouters, 2006; Ron and Walter, 2007; Rzymski and Harris, 2007) . Both IRE1 and ATF6 contribute to a transcriptional response via XBP1 and active ATF6, whereas PERK causes it by phosphorylating eukaryotic initiation factor 2a (eIF2a), a translational block that only allows selective targets to be translated such as ATF4 (Harding et al., 2003) . Several studies have demonstrated that the UPR is essential for survival under hypoxic conditions and tumors depend on an intact UPR for growth (Koumenis et al., 2002a; Lu et al., 2004; Romero-Ramirez et al., 2004; Bi et al., 2005; Blais et al., 2006) .
Using different tumor cell lines, we show here that ADAM17 mRNA and protein levels are potently induced in response to severe hypoxia and ER stressinducing agents. The induction of ADAM17 occurred as a consequence of the activation of the PERK/eIF2a/ ATF4 and ATF6 arms of the UPR and increased in tumors treated with the vascular endothelial growth factor (VEGF) inhibitory antibody Bevacizumab. Subsequently, severe hypoxia and ER stress activated ADAM17 and ectodomain shedding of TNFR1 involving mitogen-activated protein (MAP) kinases and/or ROS. These findings identify ADAM17 as a novel UPRregulated gene and link enhanced levels of sTNFR1 to tumor-associated severe stress conditions.
Results
Severe hypoxia induces expression of ADAM17 HeLa cells were exposed to different levels of hypoxia ranging from 1% O 2 to severe hypoxia (o0.1% O 2 ). ADAM17 mRNA levels were evaluated by quantitative reverse transcriptase-PCR (Figure 1a ). Mild hypoxia (1% O 2 ) only slightly induced ADAM17 mRNA levels after 24 h, although mRNA levels of known hypoxiainducible genes, such as E1B 19K/Bcl-2-binding protein Nip3 (BNIP3), were induced by 4.8-fold under 1% O 2 (Supplementary Figures 1A and B) . However, exposure to severe hypoxia resulted in a massive increase in ADAM17 mRNA levels. This response was validated in several human cell lines including HEF, HEK293, U87 and MCF7 cells (Figure 1b) . Each of the cell lines showed a time-dependent induction of ADAM17 mRNA, ranging from 3.8-fold in MCF7 to 14.2-fold in HeLa cells after 24 h of severe hypoxia.
Induction of ADAM17 by severe hypoxia was also investigated at the protein level (Figure 1c ). Immunoblotting with an antibody against ADAM17 revealed two major bands, consistent with the full-length form Figure 1 Severe hypoxia and ER stress induce expression of ADAM17. (a) HeLa cells were exposed to different concentrations of oxygen for 24 h. ADAM17 mRNA levels were examined by quantitative reverse transcriptase-PCR (qRT-PCR). Bars represent fold changes of ADAM17 mRNA normalized to TUBA6 levels. Data are presented as relative change to normoxic control (21%) (n ¼ 3, *Po0.05 versus 21%). (b) HEF, HEK, U87, HeLa and MCF7 cells were exposed to severe hypoxia (o0.1% oxygen) for the indicated periods. ADAM17 mRNA levels were examined by qRT-PCR. Bars represent fold changes of ADAM17 mRNA normalized to TUBA6 levels. Data are presented as relative change to normoxic control (0) (n ¼ 3, *Po0.05 versus 0). (c) MCF7 cells were exposed to severe hypoxia for the indicated periods or for 24 h of hypoxia followed by reoxygenation (Reox). Protein levels of ADAM17 and actin were examined by immunoblotting. (d) HeLa cells were exposed for 12 h to the HIFa-stabilizing compounds: dimethyloxalylglycine (DMOG, 100 mM), desferrioxamine (DFO) (40 mM), CoCl 2 (100 mM) or to the ER stressors MG132 (10 mM), Thapsigargin (THP, 300 nM) or Tunicamycin (TUN, 5 mg/ml). mRNA levels of ADAM17 were examined by qRT-PCR. Bars represent fold changes of ADAM17 mRNA normalized to TUBA6 levels. Data are presented as relative change to control (Ctr) (n ¼ 3, *Po0.05 versus control). (e) HeLa, MCF7 and MD231 cells were exposed to Thapsigargin (THP, 300 nM) for the indicated periods. mRNA levels of ADAM17 were examined by qRT-PCR. Bars represent fold changes of ADAM17 mRNA normalized to TUBA6 levels. Data are presented as relative change to control (0) (n ¼ 3, *Po0.05 versus 0). Figure 1C) . Interestingly, upon reoxygenation, ADAM17 levels decreased again, indicating that induction and maturation of ADAM17 is fostered by hypoxia.
Expression of ADAM17 is induced by ER stressors
In contrast to ADAM17 induction by severe hypoxia, the hypoxia-mimicking agent CoCl 2 -although able to stabilize HIF1a (Supplementary Figure 1D) -was unable to increase ADAM17 mRNA levels, whereas the iron chelator desferrioxamine (DFO), which also increased HIF1a protein (Supplementary Figure 1D) , slightly enhanced ADAM17 mRNA levels ( Figure 1d ). However, exposure to dimethyloxalylglycine (DMOG), which inhibits HIF-prolylhydroxylases leading to HIF1a stabilization (Supplementary Figure 1D) , did not affect ADAM17 expression, suggesting that ADAM17 induction by severe hypoxia might be independent of HIF1a. In line, in HeLa cells, HIF1a knockdown did not significantly reduce ADAM17 mRNA levels induced by hypoxia (Supplementary Figure 1A) . Similarly, HIF2a knockdown was ineffective in regulating ADAM17 mRNA levels under hypoxia (data not shown). In contrast, hypoxic induction of BNIP3, a known HIF target gene, was completely suppressed by HIF1a knockdown at 8 h and by 74% at 24 h exposure to hypoxia, respectively (Supplementary Figure 1B) .
As severe hypoxia can activate ER stress sensors and subsequently induce the UPR, we tested whether ER stress would affect ADAM17 expression. HeLa cells were exposed to the proteasome inhibitor MG132, the ER Ca 2 þ ATPase inhibitor Thapsigargin and the Nlinked glycosylation inhibitor Tunicamycin ( Figure 1d ). All three reagents not only enhanced the levels of the UPR-inducible transcription factor ATF4 (Supplementary Figure 1D ), but also substantially increased ADAM17 mRNA levels. ADAM17 mRNA levels were also elevated in MCF7 and MDA231 cells exposed to Thapsigargin in a time-dependent manner (Figure 1e ), similar to the situation with Tunicamycin (Supplementary Figure 1E ). Each of the cell lines stimulated with Thapsigargin for 24 h showed a significant induction of ADAM17 mRNA ranging from 4.3-fold in HeLa to 8.5-fold in MDA231 cells.
The PERK/eIF2a/ATF4 and ATF6 arms of the UPR contribute to induction of ADAM17 by ER stress and severe hypoxia To confirm the requirement of the UPR signaling pathway for the transcriptional regulation of ADAM17 during ER stress, HeLa cells were transfected with small interfering RNA (siRNA) targeting the transcription factors ATF4, XBP1 and ATF6 (Supplementary Figures 2A and B) that are activated by the PERK/eIF2a, IRE1 and ATF6 arms of the UPR, respectively. Bioinformatic analysis using MatInspector software (Genomatix, Munich, Germany) revealed putative binding sites for ATF4, ATF6 and XBP1 within the ADAM17 promoter (Supplementary Figure 2C ). ATF4 knockdown suppressed ADAM17 mRNA induction by Thapsigargin almost completely (P ¼ 0.013), and ATF6 knockdown suppressed its induction by 65% (P ¼ 0.032), whereas knockdown of XBP1 did not affect ADAM17 mRNA expression in response to Thapsigargin (Figure 2a ). In addition, knockdown of ATF4 and ATF6 prevented induction of ADAM17 protein levels in response to Thapsigargin (Figure 2b ). Concomitantly, in MCF7 cells exposed to 24 h severe hypoxia, ATF4 knockdown suppressed ADAM17 mRNA induction by 76% (P ¼ 0.004; Figure 2c ). Within the ADAM17 promoter, three potential ATF4-binding sites located at À6764, À3289 and À3130 bp relative to the transcriptional start site were predicted. To assess promoter binding of ATF4 we performed chromatin immunoprecipitation followed by quantitative PCR analysis (Figure 2d ), which revealed that hypoxia promoted ATF4 binding to the distal predicted ATF4-binding site in the ADAM17 promoter. The proximal ATF4-binding sites were not enriched in ATF4, neither under normoxic nor under hypoxic conditions.
The ability of the UPR to regulate ADAM17 mRNA levels was further investigated in cells exposed to Salubrinal, a selective inhibitor of the phosphatase complexes that dephosphorylate eIF2a (Boyce et al., 2005) . Exposure to Salubrinal for 24 h resulted in a 3.6-fold induction of ADAM17 mRNA in HeLa cells that was accompanied by increased phosphorylation of eIF2a (Supplementary Figure 2D) . ATF4 knockdown suppressed ADAM17 mRNA induction by Salubrinal by 86% in MCF7 cells (P ¼ 0.032; Figure 2e ). Similarly, in HeLa cells, PERK knockdown diminished ADAM17 mRNA induction by Thapsigargin (Supplementary Figures 2E and F) .
To validate our findings in vivo, we determined ADAM17 mRNA levels in a series of MDA231 tumor xenografts that had been treated with Bevacizumab (Avastin; Figure 2f ). This inhibitory VEGF antibody decreases tumor vascularization, which can lead to severe tumor hypoxia and induction of UPR target genes (Mujcic et al., 2009; Rzymski et al., 2010) as indicated by staining for HIF1a and the hypoxia marker carboanhydrase 9 (Supplementary Figure 2I) . Compared with control tumors, ADAM17 mRNA levels were significantly induced (P ¼ 0.009) in Bevacizumabtreated tumors.
Severe hypoxia and ER stress activate ADAM17 and ectodomain shedding of TNFR1
In a next step we tested whether severe hypoxia and ER stress were also able to increase the activity of ADAM17. In HeLa cells exposed to severe hypoxia for different time points, ADAM17 activity time dependently increased (Figure 3a) . ADAM17 activity was also significantly increased in HeLa cells after Thapsigargin treatment (Figure 3b) . Consistent with the ADAM17 is regulated by the unfolded protein response T Rzymski et al ADAM17 activity assays, exposure to Thapsigargin or severe hypoxia resulted in a pronounced increase in processed ADAM17 protein levels in MCF7 cells over time (Figures 1c and 3c) . One of the best-known physiological substrates apart from TNFa for ADAM17 is TNFR1. Concomitant with the levels of processed ADAM17 protein, Thapsigargin as well as severe hypoxia resulted in a substantial reduction in full-length, membrane-associated TNFR1 protein levels and an increase in the amounts of the remaining intracellular cleaved form of the protein (Figure 3c ). Subsequently, in HeLa cells, exposure to 24 h of severe hypoxia led to a threefold (P ¼ 0.004) increase in the levels of soluble TNFR1 in cell culture media (Figure 3d ). Similar to the situation with ADAM17 expression, TNFR1 secretion was not Figure 2 Induction of ADAM17 under ER stress and hypoxia depends on ATF4 and ATF6. (a) MCF7 cells were transfected with siRNA specific for ATF4, XBP1 or ATF6 or with control siRNA (siCtr) and exposed to Thapsigargin (300 nM) for 8 h. mRNA levels of ADAM17 were examined by quantitative reverse transcriptase-PCR (qRT-PCR). Bars represent fold changes of ADAM17 mRNA levels normalized to TUBA6 levels. Data are presented as relative change to control (siCtr) (n ¼ 3, *Po0.05, versus siCtr, # Po0.05 versus Thapsigargin siCtr). (b) MCF7 cells were transfected with siRNA specific for ATF4 and ATF6 (siATF4/6) or with siCtr and exposed to Thapsigargin for 24 h. Protein levels of ADAM17, ATF4 and actin were examined by immunoblotting. (c) MCF7 cells were transfected with siRNA specific for ATF4 or with siCtr and exposed to severe hypoxia for 24 h. mRNA levels of ADAM17 were examined by qRT-PCR. Bars represent fold changes of ADAM17 mRNA normalized to TUBA6 levels. Data are presented as relative change to normoxic control (siCtr) (n ¼ 3, *Po0.05 versus siCtr, # Po0.05 versus hypoxia siCtr). (d) Chromatin immunoprecipitation (ChIP) was performed in HeLa cells exposed to normoxia or severe hypoxia using an antibody against ATF4 or uncoupled beads (CTR). ChIP/qPCR analysis was performed using primers amplifying the region surrounding the distal predicted ATF4-binding site and are presented as percentage of the input (n ¼ 3, *Po0.05 versus normoxia). (e) MCF7 cells were transfected with siRNA specific for ATF4 or with siCtr and exposed to Salubrinal for 12 h. mRNA levels of ADAM17 were examined by qRT-PCR. Bars represent fold changes of ADAM17 mRNA normalized to TUBA6 levels. Data are presented as relative change to control (siCtr) (n ¼ 3, *Po0.05 versus siCtr, # Po0.05 versus Salubrinal siCtr). (f) Mice bearing MD231 xenograft tumors were either treated with the angiogenic inhibitor Bevacizumab or with phosphate-buffered saline (PBS; Ctr). mRNA levels of ADAM17 in the xenograft tumors were examined by qRT-PCR. Box-and-whisker plots of ADAM17 mRNA expression in tumor samples from treated and sham-treated control animals (Ctr) are displayed (n ¼ 5, *Po0.05 versus Ctr).
ADAM17 is regulated by the unfolded protein response T Rzymski et al increased by the HIFa stabilizers dimethyloxalylglycine and CoCl 2 (Figure 3e ), whereas DFO enhanced TNFR1 secretion, although this response was much less than the response to Thapsigargin or MG132. This latter finding is consistent with previous observations that DFO can slightly increase ER stress and ATF4 (Rzymski et al., Figure 3 Severe hypoxia and ER stress increase shedding activity of ADAM17 and release of soluble TNF receptor 1. (a) HeLa cells were exposed to severe hypoxia (Hyp) for the indicated periods. ADAM17 activity in cell lysates was measured by determining fluorescence of an internally quenched fluorescent substrate as indicator of enzyme activity. Fluorescence was normalized to protein content and shown as relative change to control (n ¼ 3, *Po0.05 versus normoxic control (0)). (b) HeLa cells were exposed to Thapsigargin (Thp, 300 nM) for the indicated periods and ADAM17 activity was measured (n ¼ 3, *Po0.05 versus control (0)). (c) MCF7 cells were exposed to Thapsigargin for the indicated periods (left panel) or to 24 h severe hypoxia (right panel). Protein levels of ATF4, ADAM17, TNFR1 and actin were examined by immunoblotting. (d) HeLa cells were exposed to severe hypoxia for the indicated periods. Levels of soluble TNFR1 in cell culture media were determined by quantitative sandwich enzyme-linked immunosorbent assay (ELISA) (n ¼ 3, *Po0.05 versus normoxic control (0)). (e) HeLa cells were exposed for 16 h to the HIFastabilizing compounds: dimethyloxalylglycine (DMOG, 100 mM), desferrioxamine (DFO) (40 mM), CoCl 2 (100 mM) or to the ER stressors MG132 (10 mM), Thapsigargin (THP, 300 nM) or Tunicamycin (TUN, 5 mg/l). Levels of soluble TNFR1 in cell culture media were determined by ELISA (n ¼ 3, *Po0.05 versus control (Ctr)). (f) HeLa, HCT116 and ME180 cells were exposed to Thapsigargin (Thp) for the indicated periods. Levels of soluble TNFR1 in cell culture media were determined by ELISA (n ¼ 3, *Po0.05 versus control (0)). (g) Mice bearing MD231 xenograft tumors were either treated with the angiogenic inhibitor Bevacizumab or with phosphate-buffered saline (PBS; Ctr). Levels of human sTNFR1 were determined in mouse serum by ELISA (n ¼ 3, *Po0.05 versus control (Ctr)).
ADAM17 is regulated by the unfolded protein response T Rzymski et al 2010), although in our model DFO did not enhance ATF4 (Supplementary Figure 1D) . In support, Thapsigargin treatment resulted in a robust time-dependent increase in sTNFR1 levels in HeLa, HCT116 and ME180 cells (Figure 3f ). Interestingly, human sTNFR1 levels were also enhanced in serum from xenograft-bearing mice treated with Bevacizumab compared with respective controls (Figure 3g ), indicating that this treatment enhanced the release of sTNFR1 from the xenografted tumor.
In contrast, Tunicamycin did not induce TNFR1 release (Figure 3e ). However, western blot analysis showed that Tunicamycin as an inhibitor of Nglycosylation reduced, in contrast to MG132 or Thapsigargin, ADAM17 glycosylation, which may prevent ADAM17 sheddase activity (Supplementary Figure 2G) . Together, these data demonstrate that severe hypoxia and ER stress potently increase ADAM17 activity and TNFR1 release.
Release of TNFR1 by ER stress and severe hypoxia requires UPR activation and ADAM17 metalloproteinase activity The ability of the UPR to control TNFR1 shedding was investigated in cells treated with siRNA against PERK, ATF4, IRE1 and ATF6 (Supplementary Figures 2A, B and F). Knockdown of PERK, ATF4 and ATF6 significantly suppressed TNFR1 release from HeLa cells exposed to Thapsigargin (Figure 4a ). In contrast, no significant differences were observed in IRE1 knockdown cells. Consistently with ADAM17 expression, a 24 h Salubrinal treatment of HeLa cells increased TNFR1 release (Supplementary Figure 2H) . Similarly, knockdown of PERK and ATF4 decreased hypoxiainduced sTNFR1 levels (Figure 4b) , indicating involvement of the UPR in the release of TNFR1 by ER stress and hypoxia.
Finally, to investigate the relative contribution of ADAM17 to the release of TNFR1 under hypoxia and ER stress, we treated cells with Marimastat, a broadrange metalloproteinase inhibitor that also inhibits ADAM17 (Figure 4c ). Exposure to 10 mM Marimastat prevented TNFR1 release in response to Thapsigargin by 81% (P ¼ 0.002) and to hypoxia by 62% (P ¼ 0.007). Treatment of HeLa cells with siRNA against ADAM17 resulted in a knockdown efficiency of 65% in hypoxic cells and of 80% in Thapsigargin-treated cells on the mRNA level (Supplementary Figure 3A) , and prevented Thapsigargin induction of ADAM17 protein (Supplementary Figure 3B) . Subsequently, ADAM17 knockdown suppressed TNFR1 release by 46% (P ¼ 0.039) during 24 h of Thapsigargin exposure (Figure 4d ) Figure 4 The PERK/ATF4 arm of the UPR and ATF6 contribute to the release of soluble TNFR1 by ER stress and severe hypoxia. (a) HeLa cells were transfected with siRNA specific for ATF4, PERK, IRE1, ATF6 or with control siRNA (siCtr). Cells were exposed for 16 h to Thapsigargin (300 nM). Levels of soluble TNFR1 in cell culture media were determined by enzyme-linked immunosorbent assay (ELISA; n ¼ 3, *Po0.05 versus control (siCtr)). (b) HeLa cells were transfected with siRNA specific for ATF4, PERK, ADAM17 (siA17) or with siCtr and exposed to severe hypoxia for 24 h. Levels of soluble TNFR1 in cell culture media were determined by ELISA (n ¼ 3, *Po0.05 versus normoxic control (siCtr)). (c) HeLa cells were pretreated for 2 h with the broad-spectrum metalloproteinase inhibitor, Marimastat (MAR, 10 mM) and exposed for 16 h to Thapsigargin or for 24 h to severe hypoxia. Levels of soluble TNFR1 in cell culture media were determined by ELISA (n ¼ 3, *Po0.05 versus control (Ctr), 
MAP kinases and ROS contribute to release of sTNFR1
In cells exposed to severe hypoxia or ER stress, ADAM17 was present predominantly as a mature cleaved form. Recently, it has been suggested that ectodomain shedding by ADAM17 in cancer cells can be regulated by MAP kinase pathways (Xu and Derynck, 2010) . We thus determined the contribution of MEK1/ERK and p38 MAP kinase signaling pathways in TNFR1 shedding during ER stress and severe hypoxia. Cells were treated with the MEK1 inhibitor PD98059 or the p38 MAP kinase inhibitors SB203580 and SB202190. TNFR1 release by Thapsigargin as well as by severe hypoxia was inhibited in cells treated with these inhibitors (Figures  5a and b) . Interestingly, although MAP kinase inhibitors were not sufficient to diminish ADAM17 activity (Supplementary Figure 3C) , they decreased ADAM17 protein levels in Thapsigargin-and hypoxia-treated cells (Supplementary Figures 3D and E) .
Next, we investigated the role of ROS, which are frequently found enhanced by ER stress (Gorlach et al., 2006) , in the control of sTNFR release. ROS have been suggested to contribute to sheddase activation of ADAM17 by promoting dissociation of the inhibitory prodomain from active mature ADAM17/TACE (Zhang et al., 2001) . First, we determined ROS levels in cells under ER stress. Electron paramagnetic resonance measurements revealed that Thapsigargin time dependently increased O 2 À levels in HeLa cells (Figure 5c ) with kinetics resembling the induction of TNFR1 release. Similar responses were observed with Tunicamycin and MG132 (data not shown). The relative contribution of ROS to the release of TNFR1 during ER stress was investigated in HeLa cells pretreated with the antioxidants N-acetyl-L-cysteine or ascorbate. Exposure to both antioxidants reduced TNFR1 release and ADAM17 activity by Thapsigargin (Figures 5d and e) . Concomitantly, both antioxidants reduced Thapsigargin-induced O 2 À levels (Supplementary Figure 3F) , indicating that ROS contribute to ADAM17 sheddase activity and subsequent release of sTNFR1 by Thapsigargin. This response seemed to be largely independent of MAP kinase activity, as antioxidant treatment did not affect MAP kinase phosphorylation (Supplementary Figure 3G) , and MAP kinase inhibition did not affect (in the case of MEK1/ERK) or moderately (in the case of p38 MAP kinase) affected O 2 À generation (Figure 5f ). Together, these data indicate that ROS and MAP kinases contribute to ER stress-and/or hypoxiamediated release of TNFR1 by either affecting ADAM17 activity or expression, respectively.
Discussion
Although a link between inflammation and cancer has been established for a long time, there is only recently awareness of the role of hypoxia and ER stress in these processes. The data presented here identify the protease and sheddase ADAM17 as a gene inducible by severe hypoxia and ER stress in tumor cells and as a novel target of the UPR, and provide evidence for a substantial role of ADAM17 in controlling the release of TNFR1 as a member of the inflammatory TNFa system under severe hypoxia and ER stress.
ADAM17 expression was maximal at severe hypoxic conditions, which have been associated with ER stress and activation of the UPR. In line, induction of ADAM17 expression was regulated by PERK/ATF4 and ATF6 under severe hypoxia, and this response was mimicked by pharmacological ER stressors such as Thapsigargin. In contrast to many hypoxia-induced genes, however, ADAM17 was not sensitive to depletion of HIF1a or HIF2a under these conditions, although HIF1a has been associated with the regulation of ADAM17 expression in synovial cells (Charbonneau et al., 2007) . Concomitant with our study, glioma cells exposed to severe hypoxia in an anoxic chamber increased ADAM17 expression independently of HIF1a (Szalad et al., 2009) suggesting that under severe stress conditions as they may occur in the tumor microenvironment, activation of the HIF pathway and the UPR may be separated in controlling ADAM17 expression. Interestingly, hypoxia appeared to be more potent in inducing ADAM17 than ATF4, suggesting that additional mechanisms are involved in ADAM17 regulation under hypoxia. It has been shown that SP1 can contribute to increased ADAM17 levels under severe hypoxia (Szalad et al., 2009) . In addition, the proteasomal inhibitor MG132 increased not only HIF1a and ATF4, but also ADAM17 levels (data not shown). In support, the proteasome inhibitor bortezomib increased ADAM17 shedding activity (Vahdat et al., 2010) . Thus, one might speculate that under conditions associated with proteasomal inhibition, ADAM17 levels and processing may be increased. Interestingly, not only the expression of the proconvertase furin, which is responsible for ADAM17 processing, is increased under hypoxia (McMahon et al., 2005) , but also its translocation from the Golgi to the plasma membrane (Arsenault et al., 2011) . These findings suggest that under hypoxia, several mechanisms are orchestrated to promote induction and processing of ADAM17, thus possibly contributing to the proinflammatory state, and also to enhanced invasion of hypoxic tumors. This notion is supported by our findings that ADAM17 mRNA was increased within a series of MDA231 xenografts treated with the humanized VEGF monoclonal antibody Bevacizumab (Avastin) compared with controls. In line, we previously showed that treatment of xenografts with Bevacizumab increased hypoxic areas within these tumors, resulting in upregulation of CHOP (C/EBP homologous protein), an ATF4-induced transcription factor associated with ER stress (Mujcic et al., 2009 ). These results have been confirmed in this tumor setting, and preliminary results suggested that ADAM17 may be also increased in these tumors (data not shown), further supporting a role for hypoxia and ER stress in controlling ADAM17 levels also in vivo. Interestingly, overexpression of ADAM17 ADAM17 is regulated by the unfolded protein response T Rzymski et al promoted expression and secretion of VEGF in MDA231 cells , suggesting that increased expression of ADAM17 under hypoxia or ER stress may be a compensatory survival pathway induced by the UPR in response to antiangiogenic therapies and limiting their therapeutic outcome. (a) Cells were exposed to 300 nM Thapsigargin for 16 h. Levels of soluble TNFR1 in cell culture media were determined by enzyme-linked immunosorbent assay (ELISA; n ¼ 3, *Po0.05 versus control (Ctr), # Po0.05 versus Thapsigargin Ctr). (b) Cells were exposed to severe hypoxia for 24 h. Levels of soluble TNFR1 in cell culture media were determined by ELISA (n ¼ 3, *Po0.05 versus normoxic control (Ctr), # Po0.05 versus hypoxic Ctr). (c) HeLa cells were treated with Thapsigargin for the indicated periods. Kinetics of superoxide production was measured by electron paramagnetic resonance (EPR) using 1-hydroxy-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine hydrochloride (CMH) as a spin probe (n ¼ 3, *Po0.05 versus control (0)). (d) HeLa cells were pretreated for 30 min with the antioxidants N-acetyl-L-cysteine (NAC, 5 mM) or ascorbate (ASC, 100 mM) and exposed for 16 h to Thapsigargin. Levels of soluble TNFR1 in cell culture media were determined by ELISA (n ¼ 3, *Po0.05 versus control (Ctr), # Po0.05 versus Thapsigargin Ctr). (e) HeLa cells were pretreated with ASC or NAC for 30 min and were then exposed for 16 h to Thapsigargin and ADAM17 activity was measured (n ¼ 3, *Po0.05 versus control (Ctr), # Po0.05 versus Thapsigargin-treated cells). (f) HeLa cells were pretreated for 1 h with the MEK1 inhibitor PD98059 or the p38 MAP kinase inhibitor SB202190. Cells were exposed to Thapsigargin for 6 h. Superoxide production was measured by EPR using CMH (n ¼ 3, *Po0.05 versus control (Ctr), # Po0.05 versus Thapsigargin Ctr).
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Although the clinical relevance and frequency of UPR activation in tumors is still largely unknown, ADAM17 is joining a growing number of genes regulated by the UPR and correlated with poor prognosis for cancer patients. Importantly, although we have presented evidence that ER stress and hypoxia not only induce ADAM17 expression but also increase maturation and activity of ADAM17 in cancer cells, the tumorigenic activity of ADAM17 has been associated with the ADAM17 active form and its sheddase activity. In a recent study, ADAM17 activity correlated with the advanced state of head and neck cancer (Kornfeld et al., 2011) .
Although the biological importance of increased ADAM17 sheddase activity by hypoxia and ER stress still remains to be fully investigated, one might speculate that it is directly linked to the adverse prognostic value of severe hypoxia in cancer. Interestingly, increasing evidence indicates that both hypoxia and ER stress can be the result of an inflammatory tumor response, but can conversely also cause and promote tumor inflammation (Gargalovic et al., 2006; Hu et al., 2006; Zhang and Kaufman, 2008; Li et al., 2009) . Our data show that severe hypoxia and ER stress increase the levels of sTNFR1 as a result of increased ADAM17 sheddase activity. As ADAM17 controls both TNFa production by inflammatory/immune cells and the bioavailability of TNFR on target cells, ADAM17 can be regarded as a potential key player in the control of the inflammatory response in cancer.
Whereas TNFa levels have been shown to increase in hypoxia, the concomitant increase in sTNFR1 may be indication of a fine tuning of the inflammatory tumor response under severe hypoxia. In line, our data indicate that xenograft tumors treated with Bevacizumab release increased levels of sTNFR1. In this context, ADAM17 may diminish the effects of localized inflammation around cytokine-releasing cells by shedding of receptors on the cell surface that can bind to increased levels of TNFa. The involvement of the UPR may be of specific significance in this process. It has been reported that inflammatory cytokines, including TNFa (Xue et al., 2005) , cause ER stress and therefore activate the UPR in various cancer cell lines. Thus, increased ADAM17 sheddase activity under ER stress may be a result of the negative feedback loop and an adaptive response desensitizing cells from stress-inducing stimulation.
The data presented here indicate that MAP kinases are activated by ER stress and hypoxia and contribute to induction of ADAM17 and release of TNFR1. Both ERK1/2 (extracellular signal-regulated kinases 1 and 2) and p38 MAP kinase are rapidly phosphorylated in response to ER stress and severe hypoxia (Hung et al., 2004; Chen et al., 2005; Jiang et al., 2007; Dai et al., 2009) , and activation of both MAP kinase pathways confers resistance to ER stress and ER stress-induced apoptosis (Hu et al., 2004; Chen et al., 2005) . Thus, it is tempting to speculate that induction of ADAM17 may contribute to UPR-induced resistance to ER stress and survival in the hypoxia and/or proinflammatory tumor microenvironment.
There is increasing evidence that ER stress and inflammation are interconnected by the increased production of ROS (Harding et al., 2003; Xue et al., 2005; Gorlach et al., 2006) . Our results indicate that Thapsigargin-induced ER stress increased ROS levels that correlated with the kinetics of ADAM17 sheddase activity. In fact, our studies provided evidence that ROS contribute to ADAM17 activity and the release of soluble TNFR1 in these conditions. In line, ROS were required for adenosine-5 0 -triphosphate-dependent activation of ADAM17 (Myers et al., 2009) . Intriguingly, phorbol ester activated ADAM17 shedding through enhanced ROS generation that inactivated protein disulfide isomerase and thus allowed ADAM17 to adopt an 'open' active conformation (Willems et al., 2011) . Given that Thapsigargin has been shown to promote protein disulfide isomerase cell surface localization, and that this mechanism plays an important role in controlling inflammatory responses (Peters and Raghavan, 2011) , it is tempting to speculate that ROS generation by ER stress contributes to enhanced ADAM17 activity and subsequent release of sTNFR1 as part of the inflammatory response of tumor cells toward stress conditions. In addition, it has been shown that TNFa treatment induces accumulation of ROS and that oxidative stress itself results in ER stress (Xue et al., 2005; Liu et al., 2008a) . The PERK-dependent arm of the UPR can counteract the negative effects of oxidative stress and promote tumor growth by the transcription of antioxidant and detoxifying enzymes in an NRF2-and ATF4-dependent manner (Cullinan and Diehl, 2004) . Thus, we hypothesize that induction of ADAM17 by the PERK/ATF4 arm of the UPR is a component of the survival program induced not only by a hypoxic, but also by an inflammatory, prooxidant microenvironment in tumors. Although hypoxic and inflammatory responses are tightly interconnected and both can induce UPR in a common stress response, it is unclear which specific role ROS plays in the hypoxic tumor microenvironment. Although it has been reported that the PERK/eIF2a/ATF4 integrated stress response was activated by ROS under hypoxic conditions (Liu et al., 2008b) , our findings indicate that ROS are decreased under fully hypoxic conditions, but are restored upon reoxygenation (Diebold et al., 2010) . Interestingly, our data suggest that ADAM17 levels decrease by reoxygenation following severe hypoxia, a state that has been associated with restored ROS levels. Certainly, further studies will need to address the role and significance of ROS in the increased expression and metalloproteinase activity of ADAM17 under hypoxia.
Collectively, this study identified ADAM17 as a novel UPR target in response to severe hypoxia and ER stress, and demonstrated the involvement of this pathway in the increased release of TNFR1 in severely stressed tumor cells. The knowledge gained by these studies will improve the overall understanding of how inflammatory conditions develop in hypoxic tumors. Future studies with appropriate animal models will need to address the many open questions about the role of ADAM17 and (Szlosarek and Balkwill, 2003; Burton and Libutti, 2009 ). In addition, selective ADAM17 inhibitors have already demonstrated synergistic effects with conventional anticancer therapies in preclinical models (Murphy, 2008) . Thus, targeting ER stress-dependent activation of ADAM17 may provide an attractive alternative or complementary approach for therapeutic exploitation of tumor hypoxia.
Materials and methods

Materials
Thapsigargin, Tunicamycin and MAP kinase inhibitors were from Calbiochem (Darmstadt, Germany). Salubrinal was from Santa Cruz (Heidelberg, Germany). All other chemicals were from Sigma (Taufkirchen, Germany).
Cell culture
The following human cell lines were used: HEF (embryo fibroblasts), HEK293 (embryo kidney), U87 (glioblastoma), HeLa, ME180 (cervical carcinoma), MCF7, MDA231 (breast adenocarcinoma) and HCT116 (colon carcinoma). Cells were maintained in Dulbecco's modified Eagle's medium with 1 mg/ ml glucose (PAA, Pasching, Austria) supplemented with 10% fetal calf serum (PAN Biotech GmbH, Aidenbach, Germany), penicillin (100 U/ml), streptomycin (100 mg/ml) and 4 mM L-glutamine (PAA). A humidified gas-sorted incubator-gloved box (InVivo2 400; Ruskinn, Bridgend, UK) was used for hypoxic experiments.
Transfection of siRNA For knockdown experiments, the following siRNAs were used: Silencer Negative Control #1 (siCtr), PERK (eIF2AK3) siRNA ID s18102, XBP1 siRNA ID s14913, ATF6 siRNA ID 115889 (Ambion, Darmstadt, Germany), IRE1 (ERN1) si00605248 (Qiagen, Hilden, Germany), ADAM17 siRNA ID HSS110434 (Invitrogen, Darmstadt, Germany), ATF4 sense, 5 0 -CCACGUUGGAUGACACUUGdTdT-3 0 ; ATF4 antisense, 5 0 -CAAGUGUCAUCCAACGUGGdTdT-3 0 (Eurogentec, Ko¨ln, Germany). Duplex (20 mM stock concentration) and Lipofectamin RNAiMAX (Invitrogen) (ratio 1:1) were diluted in medium, and added to the cells (30% confluency) at a final concentration of 20 nM as described (Rzymski et al., 2010) . Knockdown efficiency was between 65 and 90%. Assays were performed 48 h post transfection.
Immunoblotting
Cells were lysed and western blot analyses were performed as described (Rzymski et al., 2010) using antibodies against ADAM17/TACE (R&D Systems, Wiesbaden, Germany), TNFR1, S51-phosphorylated eIF2a or eIF2a (all from Cell Signaling, Frankfurt am Main, Germany), ATF4 and b-actin (both from Santa Cruz).
Real-time quantitative PCR RNA extraction, quantification and evaluation methods were as described (Rzymski et al., 2008 (Rzymski et al., , 2010 
Chromatin immunoprecipitation
Chromatin immunoprecipitation analysis was performed as previously described (Diebold et al., 2010) . Briefly, HeLa cells were fixed at room temperature with formaldehyde. After fixation with 0.125 M glycine, cells were pelleted, washed with phosphate-buffered saline, lysed and sonicated. Chromatin was precipitated with anti ATF4-protein A agarose beads complex for 12 h at 4 1C. Immunocomplexes were washed, eluted in buffer (50 mM Tris pH 8.0, 10 mM EDTA and 1% SDS) followed by RNaseA and proteinase K treatment. Precipitated DNA was purified with phenol/chloroform and ethanol and amplified by quantitative PCR using the primers: ADAM17 promoter 1 (ATF4 site À6764 bp) forward: 5 0 -TTAGTGGCTTCCAGGGACTG-3 0 , reverse: 5 0 -GCAATC ATCACCACCATCTG-3 0 ; ADAM17 promoter 2 (ATF4 site À3289/À3130 bp) forward: 5 0 -AGACCAACTATGGCCC AGTG-3 0 , reverse: 5 0 -TTGACAGCCACAGTGGTAGC-3 0 .
In vivo xenograft expression studies Female BALB/c severe combined immunodeficiency mice (Harlan Sprague-Dawley, Inc., Blackthorne, UK), 6 to 8 weeks old, were implanted subcutaneously with 100 ml of MDA231 cell suspension ( 10 7 ) with an equal volume of Matrigel (BD Bioscience, Oxford, UK). Tumor growth was monitored twice to thrice every week by measuring length, width and height of each tumor using calipers. When a tumor reached the maximum size (1.44 cm 2 surface area) permitted by the Home Office license, the mouse was killed, and the tumor was excised. Bevacizumab was given intraperitoneally (10 mg/ kg every 3 days) for a total of five injections starting from day 0 when the tumor cells were implanted.
Human ADAM17 activity assay Human ADAM17 activity was measured by InnoZyme TACE Activity Kit (Calbiochem) according to the manufacturer's instructions in cellular lysates. ADAM17 was captured by a monoclonal antibody against ADAM17. ADAM17 activity was measured by determining fluorescence of an internally quenched fluorescent substrate in a microplate reader (Tecan, Crailsheim, Germany) at an excitation wavelength of 324 nm and emission wavelength of 405 nm.
Human TNFR1 enzyme-linked immunosorbent assay
Concentrations of sTNFR1 in cell culture supernatants or in mouse serum were measured by Quantikine human sTNFR1 Immunoassay (R&D Systems) according to the manufacturer's instructions. Optical density was measured in a microplate reader (Tecan) set to 450 nm with wavelength correction set to 570 nm and plotted against a standard curve.
Electron paramagnetic resonance Cells were harvested in Krebs-Hepes-Tris buffer before addition of 5 mM diethyldithiocarbamate, 25 mM DFO and 100 mM spin probe 1-hydroxy-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine hydrochloride (CMH; Noxygen, Elzach, Germany). Cell suspensions were measured on Escan electron ADAM17 is regulated by the unfolded protein response T Rzymski et al paramagnetic resonance spectrometer with temperature-controlled resonator (Noxygen) with the settings: center field 3455 G, steep width 10 G, frequency 9.7690 GHz, microwave power 23.89 mW and modulation amplitude 2.93 G. Spectra were recorded over 10 min.
Statistical analysis
Data are presented as mean ± s.e.m. Results were compared by analysis of variance for repeated measurements followed by Student-Newman-Keuls t-test. Po0.05 was considered statistically significant.
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